跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2009-012001-19-DE
EUCTR2009-012001-19-DE进行中（未招募）不适用

Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.

PIERRE FABRE MEDICAMENT0 个研究点目标入组 150 人开始时间: 2009年10月23日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
150
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Diagnosis and inclusion criteria:
  • •- Chemo-naive patients from 18 years to 75 years.
  • •- Performance status KPS > or = 80.
  • •- Non-squamous histologically or cytologically (fine needle aspiration is acceptable) proven non-small cell lung cancer.
  • •- Stage IIIB (with supra-clavicular nodal metastases or pleural effusion), stage IV or relapsing (locally or distant) after a local treatment. Patients not suitable for loco-regional treatment.
  • •- Life expectancy more than 12 weeks.
  • •- Adequate bone marrow, hepatic and renal functions:
  • •o Neutrophils > or = 2.0x10 9/l , platelets > or = 100x10 9/l, Haemoglobin > 11 g/dl or 6.8 mmol/l.
  • •oTotal bilirubin < or = 1.5xULN, Transaminases < 2.5xULN, Alkaline Phosphatases < 5xULN.
  • •o Creatinine < or = ULN (if limit value, creatinine clearance > or = 60 ml/min).
  • •- Prior therapy:
  • •o Surgery: patients may have had previous surgery for NSCLC.
  • •o Chemotherapy: patients must not have had systemic chemotherapy or immunotherapy.
  • •o Radiation therapy: patient is eligible if presence of target lesions outside the irradiated area.
  • •- Presence of at least one measurable indicator lesion (RECIST criteria. Version 1.1) which has not been previously irradiated. Measurable lesions (measured in at least one dimension) (longest diameter to be recorded) as = 20 mm with conventional techniques or as = 10 mm with spiral CT scan.
  • •Physical examination and ultrasound will not be considered as objective tumour assessments.
  • •- The patient must give written (personally signed and dated) informed consent before completing any study-related procedure.
  • •- Absence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
  • •- Women of childbearing potential must be using a medically accepted method of contraception (i.e. oral contraceptives, intrauterine devices) to avoid pregnancy during the 2 months preceding the start of study treatment, throughout the study period and for up to 3 months after the last dose of study treatment in such a manner that the risk of pregnancy is minimised. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study treatment.
  • •- Fertile men must be using an effective method of birth control if their partners are women of childbearing potential during study period and up to 3 months following the last dose of treatment.
  • •- The patient must have access to social insurance according to local regulations.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •Patients with at least one of the following criteria will not be included:
  • •- A female is not eligible to enter the study if:
  • •o Pregnant or lactating.
  • •o With positive pregnancy test at inclusion.
  • •- Known hypersensitivity to the study drug(s) or to drugs with similar chemical structures.
  • •- Treatment with any investigational drug within the 30 days prior to randomisation.
  • •- Any important factor likely to modify drug absorption, e.g. surgery of GIT significant malabsorption syndrome or disease affecting the gastro-intestinal tract function.
  • •- Patients with a local relapse, which is liable to be treated by radiation therapy.
  • •- Previous radiotherapy in the only site used to assess response.
  • •- Radiotherapy within the previous 4 weeks.
  • •- Clinically relevant cardiovascular, hepatic, neurological or other systemic disease making implementation of the protocol difficult.
  • •o Active central nervous system disorder, brain metastasis or leptomeningeal involvement.
  • •o Symptomatic neuropathy (sensory) > grade 1 according to the NCI Common Toxicity Criteria (NCI – CTC version 2).
  • •o Concomitant/uncontrolled medical disorder (cardiac failure or myocardial infarction within the previous 3 months, uncontrolled hypertension or arrhythmia, uncontrolled hypercalcaemia, active infection requiring i.v. antibiotics within 2 weeks before the beginning of treatment).
  • •o Weight loss > 10% within the previous 3 months.
  • •o Superior vena cava syndrome.
  • •o Long term oxygen therapy.
  • •o Pre-existing symptomatic pleural effusion requiring tapping.
  • •o Ascites or pericardial effusion.
  • •- History of another malignancy within the past five years except basal cell carcinoma of the skin or carcinoma in situ of the cervix.

研究者

相似试验

进行中（未招募）
不适用
Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-012001-19-CZPIERRE FABRE MEDICAMENT150
进行中（未招募）
1 期
Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type. - NDocally advanced or metastatic NSCLC with non squamous histological typeMedDRA version: 12.1Level: LLTClassification code 10061873Term: Non-small cell lung cancer
EUCTR2009-012001-19-ITPIERRE FABRE MEDICAMENT150
进行中（未招募）
不适用
Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.MedDRA version: 12.0Level: PTClassification code 10061873Term: <Manually entered code. Term in E.1.1>
EUCTR2009-012001-19-PTPIERRE FABRE MEDICAMENT150
进行中（未招募）
不适用
Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.MedDRA version: 14.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-012001-19-ATPIERRE FABRE MEDICAMENT150
进行中（未招募）
1 期
Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.MedDRA version: 12.0Level: PTClassification code 10061873Term: <Manually entered code. Term in E.1.1>
EUCTR2009-012001-19-FRPIERRE FABRE MEDICAMENT150